Literature DB >> 3759529

Medulloblastoma: the Duke University Medical Center experience.

B W Hershatter, E C Halperin, E B Cox.   

Abstract

We have reviewed the clinical experience in the treatment of medulloblastoma with radiotherapy at Duke University Medical Center. One hundred and twenty-seven patients treated between January 1, 1940 and December 31, 1983 were evaluated. The irradiation technique was reviewed and all irradiation doses were recalculated as minimum tumor doses in Gray (Gy). The mean follow-up was 24.4 years and the median follow-up was 26.5 years. The energy of the treatment machine was known in 102 cases. Sixty patients were treated with orthovoltage equipment and 42 patients were treated with megavoltage equipment. As a gross assessment of the impact of the details of radiotherapy treatment upon outcome, patients were grouped into excellent, good, fair, and poor treatment groups. Patients undergoing cranio-spinal axis (CSA) irradiation and receiving greater than or equal to 52 Gy to the posterior fossa and greater than or equal to 30 Gy to the clinically uninvolved remainder of the CSA were classified as having "excellent" technique. Patients undergoing CSA irradiation and receiving 40 to 52 Gy to the posterior fossa and greater than or equal to 20 Gy to the remainder of the CSA were classified as "good." Patients receiving 20 to 40 Gy to the posterior fossa and greater than or equal to 10 Gy to the spinal axis with or without prophylactic cranial irradiation were designated "fair." Any patient not fulfilling the above minimum criteria was categorized as "poor." The actuarial 5-year survival for the entire population was 33%. The 10-year survival was 21%. In 93 patients for whom records were detailed enough to allow categorization of treatment technique, 5-year actuarial survivals were: Excellent 37% (n = 17), Good 55% (n = 13), Fair 35% (n = 23), Poor 20% (n = 40). A complete surgical resection was not correlated with improved disease-free survival (DFS) in the excellent and good groups, but was correlated with an improved DFS in the fair and poor groups. The posterior fossa accounted for 62% of the failures in the 55 patients completing irradiation where the initial site of failure was known. An examination of patterns of failure in the spinal canal failed to demonstrate a dose response relationship above 10 Gy for spinal canal prophylactic irradiation. No patient developed recurrence beyond their period of risk as defined by "Collins' Law."(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3759529     DOI: 10.1016/0360-3016(86)90318-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

Review 1.  Toward a cure for infants with brain tumours: the challenge for the 1990's.

Authors:  P M Zeltzer
Journal:  Br J Cancer Suppl       Date:  1992-08

2.  Brain tumor survival: results from the National Cancer Data Base.

Authors:  T S Surawicz; F Davis; S Freels; E R Laws; H R Menck
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

Review 3.  The clinical importance of medulloblastoma extent of resection: a systematic review.

Authors:  Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

4.  Medulloblastoma: survival and late recurrence after the Collins' risk period.

Authors:  S Nishio; T Morioka; I Takeshita; M Fukui
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

5.  CNS-85 trial: a cooperative pediatric CNS tumor study--results of treatment of medulloblastoma patients.

Authors:  S Pezzotta; L Cordero di Montezemolo; R Knerich; M Arrigoni; A Barbara; L Besenzon; A Brach del Prever; P Fidani; D Locatelli; G Loiacono; L Magrassi; G Perilongo; L Rigobello; A Urgesi; E Madon
Journal:  Childs Nerv Syst       Date:  1996-02       Impact factor: 1.475

6.  Is medulloblastoma the same tumor in children and adults?

Authors:  M T Giordana; P Cavalla; A Dutto; L Borsotti; A Chiò; D Schiffer
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

7.  PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.

Authors:  Dolores Hambardzumyan; Oren J Becher; Marc K Rosenblum; Pier Paolo Pandolfi; Katia Manova-Todorova; Eric C Holland
Journal:  Genes Dev       Date:  2008-02-15       Impact factor: 11.361

8.  Medulloblastoma in children and in adults: a comparative study.

Authors:  A Maleci; L Cervoni; R Delfini
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

9.  Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review.

Authors:  Fabio Girardi; Claudia Allemani; Michel P Coleman
Journal:  J Glob Oncol       Date:  2019-10

10.  Characterisation of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas.

Authors:  S Moriuchi; K Shimizu; Y Miyao; T Hayakawa
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.